Roche#39;s Tocilizumab fails to meet primary end points for COVID-19 associated pneumonia

Roche#39;s Tocilizumab fails to meet primary end points for COVID-19 associated pneumonia
Roche#39;s Tocilizumab fails to meet primary end points for COVID-19 associated pneumonia However, Roche said there was a positive trend in time to hospital discharge in patients treated with Actemra. The median time to discharge or ‘ready to discharge’ for Actemra was 20 days and for placebo was 28 days.